

Results of General Meeting

Neurotech International Limited (ASX: NTI) ("Neurotech" or "the Company") today held a General Meeting of Members at the offices of BDO Australia – Level 25, 35 Collins Street, Melbourne VIC 3000.

All resolutions were determined by a poll.

The outcome of each resolution put to shareholders at the General Meeting is set out in the Annexure which accompanies this release.

Authority

This announcement was authorised for release by Alessandra Gauvin, Company Secretary of Neurotech International Limited.

For further information contact us via info@neurotechinternational.com

About Neurotech

Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominantly on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. Neurotech has completed a Phase II/III randomised, double-blind, placebo-controlled clinical trial in Autism Spectrum Disorder (ASD) with clinically meaningful and statistically significant benefits reported across a number of clinically-validated measures and excellent safety. In addition, Neurotech has completed and reported statistically significant and clinically meaningful Phase I/II trials in ASD and Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. Neurotech has received human ethics committee clearance for a Phase III Clinical Study in ASD.

For more information about Neurotech please visit <http://www.neurotechinternational.com>.

Disclosure of Proxy Votes

Neurotech International Limited

General Meeting

Thursday, 12 March 2026



GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E hello@automic.com.au

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

			Proxy Votes				Poll Results (if applicable)			Results
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 RATIFICATION OF PLACEMENT SHARES ISSUED UNDER LISTING RULE 7.1 CAPACITY	P	42,925,252	38,718,518 90.20%	4,135,662 9.63%	27,693,572	71,072 0.17%	38,789,590 90.37%	4,135,662 9.63%	27,693,572	Carried
2 RATIFICATION OF PLACEMENT SHARES ISSUED UNDER LISTING RULE 7.1A CAPACITY	P	42,925,252	38,718,518 90.20%	4,135,662 9.63%	27,693,572	71,072 0.17%	38,789,590 90.37%	4,135,662 9.63%	27,693,572	Carried
3 APPROVAL FOR DIRECTOR PARTICIPATION IN PLACEMENT – MR MARK DAVIES	P	69,753,664	36,778,302 52.73%	5,210,718 7.47%	11,808,017	27,764,644 39.80%	64,542,946 92.53%	5,210,718 7.47%	11,808,017	Carried
4 APPROVAL FOR DIRECTOR PARTICIPATION IN PLACEMENT – DR ANTHONY FILIPPIS	P	81,546,681	48,571,319 59.56%	5,210,718 6.39%	15,000	27,764,644 34.05%	76,335,963 93.61%	5,210,718 6.39%	15,000	Carried
5 APPROVAL FOR DIRECTOR PARTICIPATION IN PLACEMENT – MR GERALD QUIGLEY	P	81,546,681	48,571,319 59.56%	5,210,718 6.39%	15,000	27,764,644 34.05%	76,335,963 93.61%	5,210,718 6.39%	15,000	Carried
6 APPROVAL FOR DIRECTOR PARTICIPATION IN PLACEMENT – MR ROBERT MAXWELL JOHNSTON	P	80,513,348	47,537,986 59.04%	5,210,718 6.47%	1,048,333	27,764,644 34.48%	75,302,630 93.53%	5,210,718 6.47%	1,048,333	Carried
7 APPROVAL TO ISSUE FURTHER PLACEMENT SHARES	P	76,546,681	43,390,263 56.68%	5,391,774 7.04%	5,015,000	27,764,644 36.27%	71,154,907 92.96%	5,391,774 7.04%	5,015,000	Carried

